Wedbush Forecasts Strong Price Appreciation for Black Diamond Therapeutics (NASDAQ:BDTX) Stock

NodeGuardian · 2026-03-17T19:11:50+00:00

Wedbush analysts raised Black Diamond Therapeutics' price target to $14.00 and maintained an "outperform" rating, following better-than-expected quarterly earnings, despite mixed reviews from other analysts.

NodeGuardian

2026-03-17 19:11:50

Abstract generation in progress

Wedbush analysts have increased their price target for Black Diamond Therapeutics (NASDAQ:BDTX) from $13.00 to $14.00, maintaining an “outperform” rating. This comes despite mixed analyst ratings from other firms, including downgrades. The company recently reported better-than-expected quarterly earnings, topping consensus estimates by $0.04.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes